Quantcast

Industry news that matters to you.  Learn more

Cancer Biomarker Study Data Presented at the 2012 AACR Meeting

Reading time: 2 – 4 minutes

A roundup of five research studies on cancer biomarkers that were presented early last week at the American Association for Cancer Research (AACR) 103nd Annual Meeting in Chicago, Illinois.

  • Baseline Hormone Levels Appear to Predict Survival in Metastatic, Castration-resistant Prostate Cancer
    Researchers at the University of California-San Francisco Helen Diller Family Comprehensive Cancer Center presented data showing that castration-resistant prostate cancer patients with high baseline hormone levels who were treated with the androgen inhibitor abiraterone had longer overall survival compared with patients with low hormone levels. The biomarker (adrenal androgens) provided a meaningful method for patient stratification.

    Source: AACR

  • Older Patients With Certain Breast Cancer Subtype May Not Benefit From Radiation Therapy
    Ontario Cancer Institute scientists performed molecular subtyping on tumor blocks from breast cancer patients and then followed them for 10 years. The investigators found that radiation therapy did not add benefit for patients with luminal A subtype but did add benefit for patients with all other breast cancer subtypes. The researchers recommend routine testing for biomarker Ki-67 for patients with breast cancer.

    Source: AACR

  • Biomarker Identified in Relation to Drug Response in Refractory Urothelial Cancer
    Researchers from Fondazione IRCCS Istituto Nazionale dei Tumori in Milan, Italy, showed that the antiangiogenic drug pazopanib demonstrated clinically meaningful activity in patients with refractory urothelial cancer, and that circulating interleukin-8 may be an biomarker of tumor resistance and poor survival. However, further validation is needed in a large patient population.

    Source: AACR

  • Unexpected MEK1 Mutations Not Cause of Potent Melanoma Drug Resistance
    Investigators from the University of California, Los Angeles Jonsson Comprehensive Cancer Center presented data showing that a genetic mutation in MEK1 does not prevent response to BRAF inhibitors in patients undergoing treatment for BRAF-mutated melanomas. The data suggests that, contrary to current thought, the presence of both mutated MEK1 and mutated BRAF may not be a biomarker for BRAF inhibitor resistance in melanomas.

    Source: AACR

  • Novel Technology Allows for Noninvasive Imaging of Prostate Cancer
    Memorial Sloan-Kettering Cancer Center scientists described the use of a novel, noninvasive imaging tool that allowed them to measure a biomarker (free prostate-specific antigen) in prostate cancer models and to visualize bone metastasis in a tumor-specific manner. The technology could allow physicians to monitor treatment efficacy.

    Source: AACR